Respiratory Virus Activity — United States, July 2025–June 2026

Amber K. Winn, DrPH1; Onika Anglin, MPH1; Erin L. Anderson, MSPH1; Mila M. Prill, MSPH1; Monica E. Patton, MD1,2; Heidi L. Moline, MD1,2; Michael Melgar, MD1; Kevin C. Ma, PhD1; Clinton R. Paden, PhD1; Lydia J. Atherton, DVM, PhD1; Diba Khan, PhD1; Christopher A. Taylor, PhD1; Ayzsa Tannis, MPH1,2; Jasmine D. Ruffin, MPH1; Leah A. Goldstein, MPH1,3; Emily D. Carter, PhD1; Li Deng, PhD1; Gordana Derado, PhD1; Emily H. Koumans, MD1; Benjamin J. Silk, PhD1,2; Natalie J. Thornburg, PhD1; Caelin A. Cubenas, PhD1; Fatimah S. Dawood, MD1,2; Coronavirus and Other Respiratory Viruses Division Laboratory Genomic Surveillance Group (View author affiliations)

View suggested citation

Summary

What is already known about this topic?

CDC monitors the timing and severity of respiratory viral illnesses using data from six complementary public health surveillance systems.

What is added by this report?

Respiratory syncytial virus (RSV) and SARS-CoV-2 continue to cause severe health outcomes, especially among young children and older adults. During 2025–2026, RSV activity occurred later and cumulative RSV-associated hospitalization rates were lower than those during 2022–2025. SARS-CoV-2 circulated nationally with bimodal peaks in most regions. Most U.S.-sequenced SARS-CoV-2 viruses were JN.1-lineage descendants; this is the second consecutive year during which a major SARS-CoV-2 strain replacement did not occur.

What are the implications for public health practice?

Annually, RSV and SARS-CoV-2 circulate with distinct timing and varying severity. Effective prevention, treatment, and preparedness strategies require continued monitoring; staying current with recommended vaccinations can prevent severe respiratory virus infections.

Article Metrics
Altmetric:

Related Materials

Abstract

Respiratory viral illnesses are common and can lead to severe outcomes, including hospitalization and death. U.S. trends in respiratory virus activity during July 2025–June 2026 were analyzed using data from six complementary public health surveillance systems. Respiratory syncytial virus (RSV) activity occurred unusually late in most U.S. regions. SARS-CoV-2 circulated nationally with typical bimodal peaks that occurred in August 2025 and January 2026. Annual RSV-associated hospitalization rates (number of hospitalizations per 100,000 persons) were highest among infants aged <12 months (790.2; 95% CI = 757.9–825.3), followed by children aged 12–23 months (611.9; 95% CI = 586.3–639.8) and adults aged ≥75 years (352.1; 95% CI = 309.9–407.7). Annual RSV rates overall and by age group did not exceed those observed during 2022–2025. COVID-19–associated hospitalization rates were highest among adults aged ≥75 years (361.2), infants aged <6 months (173.3), and adults aged 65–74 years (111.4). Newly established 2025–2026 national pediatric mortality surveillance provisionally identified 34 RSV-associated pediatric deaths from 35 reporting jurisdictions and 31 COVID-19–associated pediatric deaths from 43 reporting jurisdictions. RSV sequencing did not identify variant substitutions associated with reduced susceptibility to the available RSV monoclonal antibodies for infants. Most SARS-CoV-2 lineages were JN.1 descendants, but detections of BA.3.2, a highly divergent SARS-CoV-2 variant, increased. Circulation of other respiratory viruses followed usual historical patterns. Staying current with recommended RSV and COVID-19 vaccinations reduces the risk for severe illness and disease caused by these viruses.

Introduction

Although respiratory viruses usually cause mild to moderate illness, infections are common and can result in severe lower respiratory tract disease leading to hospitalization and death. Respiratory virus seasonality varies annually, with implications for timing of vaccination and health care system preparedness. CDC monitors U.S. activity of respiratory syncytial virus (RSV); SARS-CoV-2; human metapneumovirus (hMPV); rhinoviruses and enteroviruses (RVs/EVs); parainfluenza viruses (PIVs) types 1–4; common human coronaviruses (HCoVs) 229E, NL63, OC43, and HKU1; and respiratory adenoviruses (1). This report summarizes U.S. trends in respiratory virus activity and associated morbidity and mortality during July 2025–June 2026. CDC provides a separate summary of influenza activity.

Methods

Data Sources

Data reported to CDC for weeks ending July 5, 2025–June 27, 2026 (as of July 22, 2026, unless otherwise specified) were analyzed from six public health surveillance systems: 1) National Respiratory and Enteric Virus Surveillance System (NREVSS), 2) RSV Hospitalization Surveillance Network (RSV-NET), 3) COVID-19 Hospitalization Surveillance Network (COVID-NET), 4) New Vaccine Surveillance Network (NVSN), 5) RSV- and COVID-19–associated pediatric mortality, and 6) RSV and SARS-CoV-2 genomic sequencing (Supplementary Box). Prior annual RSV laboratory data (2016–2025) and hospitalization data (2022–2025) for each July–June 12-month period were included for comparison.

Data Analysis

Respiratory virus activity. Aggregate reverse transcription–polymerase chain reaction (RT-PCR) test results for SARS-CoV-2, RSV, RV/EV, respiratory adenovirus, PIV, HCoV, and hMPV reported to NREVSS by clinical, reference, and public health laboratories throughout the United States were summarized. RSV season onset and offset were identified, respectively, as the week ending date corresponding to the first and last of 2 consecutive weeks when the percentage of weekly test results positive for RSV was ≥3%. The respiratory virus season peak was defined as the week with the highest percentage of test results positive for a respiratory virus. If a virus circulated with two bimodal peaks, the highest percentage of both peaks was identified.

Hospitalizations (among all age groups) and deaths (among children aged <18 years) associated with RSV and COVID-19. Total and age-stratified laboratory-confirmed RSV- and COVID-19–associated hospitalization rates were analyzed using data from three population-based public health surveillance systems: RSV-NET and COVID-NET (residents of any age in predefined catchment areas with laboratory-confirmed RSV or SARS-CoV-2 infection, respectively) and NVSN (active, population-based sentinel surveillance of children aged <18 years with acute respiratory illness, with systematic testing by protocol). Provisional data reported as of August 11, 2026, for confirmed pediatric deaths that meet clinical and laboratory criteria for RSV or COVID-19 occurring during September 28, 2025–June 30, 2026, were analyzed. Participating jurisdictions include those that did not identify any deaths. Thirty-one jurisdictions conducted retrospective surveillance for deaths occurring during September 28, 2025–June 30, 2026; however, some deaths are likely missed because counts are provisional.

Modeling estimates. Interim national RSV and COVID-19 illnesses, outpatient visits, hospitalizations, and deaths were estimated using previously described mathematical and statistical models (1). A multiplier model was applied to a hierarchical Bayesian conditional autoregressive–random effects model of RSV-NET and COVID-NET hospitalizations. RSV rates were adjusted for undertesting among hospitalized persons with respiratory illness at RSV-NET sites. NVSN systematically tests for RSV, whereas RSV-NET testing is based on clinician ordering practices. COVID-19 rates were not adjusted for undertesting because testing for SARS-CoV-2 among hospitalized patients with respiratory illness in COVID-NET historically has been sufficiently complete.

RSV and SARS-CoV-2 genomic sequencing and analysis. RSV subtyping and sequencing results were analyzed to estimate RSV variant prevalences. SARS-CoV-2 sequencing results were analyzed to estimate SARS-CoV-2 variant prevalences.

All data were analyzed using SAS (version 9.4; SAS Institute). This activity was reviewed by CDC, deemed not research, and conducted consistent with applicable federal law and CDC policy.*

Results

Positive Laboratory Test Results

All viruses. During weeks ending July 5, 2025–June 27, 2026, a single peak in the weekly percentage of positive test results was observed for RSV, hMPV, and HCoV. Bimodal peaks were observed for SARS-CoV-2, RV/EV, and PIV (Figure 1).

RSV. Among 2,965,708 RSV PCR test results reported to NREVSS by 273 laboratories, 118,014 (4.0%) were positive (weekly range = 0.2%–9.0%). Nationally, RSV season onset occurred during the week ending November 29, 2025. Activity peaked during the week ending February 28, 2026, and season offset occurred during the week ending April 25, 2026 (Supplementary Table 1). Nationally and by U.S. Department of Health and Human Services (HHS) region, season onset, peak, and offset occurred later during 2025–2026 than during past seasons (Figure 2) (Supplementary Table 1).

SARS-CoV-2. Among 3,125,738 SARS-CoV-2 PCR test results reported to NREVSS by 285 laboratories, 136,081 (4.4%) were positive. Nationally, the highest percentage of positive results (12.1%) occurred during the week ending August 23, 2025, and the lowest (i.e., the trough; 2.9%) during the week ending November 1, 2025 (Figure 1). A second peak (5.3% positive) occurred during the week ending January 24, 2026, followed by a trough (0.8%) during the week ending May 30, 2026. By HHS region, the occurrence of the first peak ranged from week 33 (region 6) to week 36 (regions 1–3, 5, and 10), the second peak varied from week 53 (region 6) to week 6 (region 2); no second peak occurred in regions 9 or 10.

RVs/EVs and PIVs. The RV/EV season peak occurred in fall (week ending September 20, 2025) and spring (week ending May 9, 2026) (weekly percentage positive range = 10.8%–30.3%). The season peaks for PIV types 1–4 occurred in winter (week ending November 8, 2025) and spring (week ending June 13, 2026) (weekly range = 0.9%–6.5%).

hMPV, HCoVs, and respiratory adenoviruses. The national hMPV season peak occurred during spring (week ending April 4, 2026; range = 0.4%–6.4%). The season peak for HCoVs occurred during winter (week ending February 21, 2026; range = 0.3%–10.3%). A pattern of increased activity for respiratory adenoviruses was not observed in 2026.

Outpatient Illnesses, Hospitalizations, and Deaths

RSV. During July 5, 2025–June 27, 2026, RSV was associated with an estimated 2.8–5.8 million outpatient visits, 170,000–340,000 hospitalizations, and 9,900–25,000 deaths nationally. RSV-NET–estimated cumulative RSV-associated hospitalization rates (number of hospitalizations per 100,000 persons) were highest among infants aged 0–11 months (790.2; 95% CI = 757.9–825.3), children aged 12–23 months (611.9; 95% CI = 586.3–639.8), and adults aged ≥75 years (352.1; 95% CI = 309.9–407.7) (Figure 3). NVSN-estimated pediatric hospitalization rates were highest among infants aged 0–11 months (955.9; 95% CI = 825.7–1,097.0) and children aged 12–23 months (605.4, 95% CI = 515.1–701.4).

Annual RSV-associated hospitalization rates from RSV-NET for 2025–2026 (97.3 per 100,000) were lower than were those for 2022–2025 overall (annual rate range = 99.02–132.9), and 2025–2026 rates were lowest among persons aged <18 years (Figure 3) (Supplementary Table 2). Similarly, 2025–2026 pediatric NVSN-estimated RSV hospitalization rates were lower than were those during 2022–2025.

As of August 11, 2026, 34 RSV-associated deaths among children during September 28, 2025–June 30, 2026, were provisionally reported by 35 jurisdictions. Among these 34 children, 19 (55.9%) had at least one underlying medical condition; 16 (47.1%) were hospitalized; and the median age at death was 1 year (range = 1 month–17 years). Underlying medical conditions were unknown for three children, and hospitalization status was unknown for two children. Among the 17 infants who had been age-eligible (aged <8 months on or after October 1, 2025) before they died, three had received any recommended RSV monoclonal antibodies (nirsevimab or clesrovimab), 11 infants had received none, and receipt was unknown for three infants.

COVID-19. During October 1, 2025–June 20, 2026, COVID-19 resulted in an estimated 4.1–12.4 million illnesses, 830,000–2.3 million outpatient visits, 130,000–240,000 hospitalizations, and 14,000–41,000 deaths, nationally. COVID-NET–estimated cumulative COVID-19–associated hospitalization rates (Supplementary Box) were highest among adults aged ≥75 years (361.2 per 100,000), infants aged <6 months (173.3), adults aged 65–74 years (111.4), and children aged 6–23 months (67.3) (Figure 3). NVSN-estimated pediatric hospitalization rates were highest among infants aged <6 months (174.2; 95% CI = 112.3–241.1), followed by children aged 6–23 months (67.1; 95% CI = 46.1–92.2).

As of August 11, 2026, 31 COVID-19–associated deaths among children had been provisionally reported from 43 jurisdictions. Among the 31 children who died, 23 (74.2%) had at least one underlying medical condition; 12 (38.7%) were hospitalized; and the median age at death was 9 months (range = 1 month–16 years). Underlying medical conditions were unknown for two children. Among the 20 children who had been age-eligible for vaccination (aged ≥6 months) before they died, vaccination status was unknown for two children, and none of the others had received a COVID-19 vaccine.

RSV Subtypes and SARS-CoV-2 Lineages

Among 630 CDC-subtyped RSV specimens shared with CDC from 16 U.S. jurisdictions, 408 (64.8%) were positive for RSV-A, 204 (32.4%) were positive for RSV-B, and 18 (2.9%) were positive for both A and B. Of 401 CDC-sequenced RSV samples, RSV-A genomes primarily belonged to three distinct clades (A.D.1, A.D.3, and A.D.5), and RSV-B genomes to a B.D.E.1 clade. In RSV B, three substitutions within the nirsevimab binding site (antigenic site Ø), I206M, Q209R, and S211N, reflect ongoing viral evolution. Substitutions within the clesrovimab binding sites (antigenic site IV) remained rare (<1%). No substitutions associated with reduced susceptibility to RSV monoclonal antibodies available for RSV prevention among infants were detected.

A total of 29,023 SARS-CoV-2 sequences for July 6, 2025–June 6, 2026, from 56 U.S. jurisdictions and CDC were analyzed. CDC sequenced 2,078 samples through the National SARS-CoV-2 Strain Surveillance program and identified no major SARS-CoV-2 strain replacement. All SARS-CoV-2 lineages circulating at ≥1% prevalence were JN.1 descendant lineages, except for BA.3.2 (prevalence = 8%; 95% CI = 4%–17%), during the 4 weeks ending June 6, 2026. The BA.3.2 divergent SARS-CoV-2 variant has 70–75 substitutions and deletions in the gene sequence of the spike protein relative to JN.1 and LP.8.1, a descendant of JN.1. As of August 31, 2026, CDC is monitoring BA.3.2 spread through multimodal genomic surveillance. XFG was the only lineage to attain >50% prevalence during July 2025–June 2026; a descendant lineage, XFG.1.1, increased in prevalence in 2026 as of June 6, 2026.

Discussion

Analysis of national public health surveillance data found that respiratory virus activity based on laboratory testing trends for hMPV, RVs/EVs, PIVs, and HCoVs followed expected patterns. RSV activity occurred later than expected in most U.S. regions, consistent with patterns observed in Europe (2). RSV severity, based on RSV-associated hospitalization rates, was not higher than that in recent seasons. The atypical 2025–2026 RSV seasonality highlights the importance of timely, comprehensive surveillance to guide public health decision-making. CDC recommends that infants experiencing their first RSV season receive protection against severe RSV disease through either maternal vaccination (Abrysvo, Pfizer Inc.) during September–January or infant vaccination with a monoclonal antibody (nirsevimab or clesrovimab) during October–March in most of the United States (3). Recommendations include flexibility for jurisdictional public health authorities to adjust administration timing based on local RSV epidemiology, including early or late activity (3). During 2025–2026, most U.S. jurisdictions extended the use of RSV antibodies into April to protect eligible infants. Older adults remain at increased risk for RSV-associated hospitalization; a single dose of RSV vaccine is recommended for all adults aged ≥75 years and adults aged 50–74 years who are at increased risk for severe RSV disease (4).

During 2025–2026, national bimodal SARS-CoV-2 peaks continued in late summer (August) and winter (January); in some regions, only a single peak occurred. The 2025–2026 surveillance period marked the second consecutive year without a major U.S. SARS-CoV-2 strain replacement event (5). The 2026–2027 COVID-19 vaccines are based on the JN.1-lineage XFG variant and are expected to provide protection against severe disease (6–8). Staying current with COVID-19 vaccination remains important for reducing the risk for severe COVID-19, especially among adults aged ≥65 years and those at increased risk for severe illness. The recommended number and timing of 2026–2027 COVID-19 vaccine doses vary by age (9), vaccination history, and immune status; health care providers should consult current CDC guidance.

Limitations

The findings in this report are subject to at least four limitations. First, NREVSS is a passive and voluntary public health surveillance system; data from participating laboratories vary by season and might not represent all geographic areas or age groups. Second, NVSN and RSV-NET have different catchment areas and generate hospitalization estimates using different methods; point estimates might vary. Third, genomic surveillance estimates are imprecise because of limited SARS-CoV-2 specimen availability. Finally, because RSV- and COVID-19–associated pediatric mortality data are still provisional since national reporting began in March 2026, cases are likely undercounted. Although some systems have overlapping catchment areas, each system measures a distinct metric of respiratory illness and overlap allows for periodic data validation.

Implications for Public Health Practice

Core prevention strategies to reduce respiratory virus infection risk are essential practices recommended for everyone. These include staying current with recommended vaccinations, washing hands regularly and cleaning commonly touched surfaces, optimizing ventilation in places where persons live and work, and staying home and away from others when ill with a respiratory illness. Antiviral treatments for COVID-19 are available and remain underused (10); early treatment for persons at increased risk for severe disease can moderate symptoms and prevent complications. CDC provides weekly updates of respiratory illness activity in the United States.

Acknowledgments

Participants, collaborators, and contributors to the National Respiratory and Enteric Virus Surveillance System, Respiratory Syncytial Virus Hospitalization Surveillance Network, COVID-19 Hospitalization Surveillance Network, New Vaccine Surveillance Network, Respiratory Syncytial Virus– and COVID-19–associated pediatric mortality surveillance, and U.S. national genomic surveillance.

Coronavirus and Other Respiratory Viruses Division Laboratory Genomic Surveillance Group

Megha Aggarwal, National Center for Immunization and Respiratory Diseases, CDC; Carla Bartlett, National Center for Immunization and Respiratory Diseases, CDC; Juan Castro, National Center for Immunization and Respiratory Diseases, CDC; Peter W. Cook, National Center for Immunization and Respiratory Diseases, CDC; Anna Kelleher, National Center for Immunization and Respiratory Diseases, CDC; Ana Paula Lourenco, National Center for Immunization and Respiratory Diseases, CDC; Xiaoyan Lu, National Center for Immunization and Respiratory Diseases, CDC; Paritra Mandal, National Center for Immunization and Respiratory Diseases, CDC; Julianna Marotta, National Center for Immunization and Respiratory Diseases, CDC; Casey Smith, National Center for Immunization and Respiratory Diseases, CDC.

Corresponding authors: Amber K. Winn, vtj2@cdc.gov; Fatimah S. Dawood, hgj0@cdc.gov.


1Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC; 2U.S. Public Health Service, Rockville, Maryland; 3Great Hills Solutions, LLC, Chantilly, Virginia.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Christopher A. Taylor reports that he is a trustee of a family trust that holds stock in Pfizer, Amgen, and Lilly. No other potential conflicts of interest were disclosed.


* 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

References

  1. Silk BJ, Prill MM, Winn AK, et al. Respiratory virus activity—United States, July 1, 2024–June 30, 2025. MMWR Morb Mortal Wkly Rep 2026;75:77–84. https://doi.org/10.15585/mmwr.mm7506a2 PMID:41712508
  2. European Centre for Disease Prevention and Control. Weekly bulletin: overview of respiratory virus epidemiology in the EU/EEA. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2026. https://www.ecdc.europa.eu/sites/default/files/documents/communicable-disease-threats-report-week-26-2026.pdf
  3. Moulia DL, Link-Gelles R, Chu HY, et al. Use of clesrovimab for prevention of severe respiratory syncytial virus–associated lower respiratory tract infections in infants: recommendations of the Advisory Committee on Immunization Practices—United States, 2025. MMWR Morb Mortal Wkly Rep 2025;74:508–14. https://doi.org/10.15585/mmwr.mm7432a3 PMID:40880502
  4. Britton A, Roper LE, Kotton CN, et al. Use of respiratory syncytial virus vaccines in adults aged ≥60 years: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:696–702. https://doi.org/10.15585/mmwr.mm7332e1 PMID:39146277
  5. Shakya M, Ma KC, Hughes LJ, et al. Early detection and surveillance of the SARS-CoV-2 variant BA.3.2—worldwide, November 2024–February 2026. MMWR Morb Mortal Wkly Rep 2026;75:130–7. https://doi.org/10.15585/mmwr.mm7510a1 PMID:41855090
  6. Food and Drug Administration. COVID-19 vaccines (2026–2027 formula) for use in the United States beginning in fall 2026. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2006. https://www.fda.gov/vaccines-blood-biologics/industry-biologics/covid-19-vaccines-2026-2027-formula-use-united-states-beginning-fall-2026.
  7. Irving SA, Rowley EAK, Chickery S, et al. Effectiveness of 2024–2025 COVID-19 vaccines in children in the United States—VISION, August 29, 2024–September 2, 2025. MMWR Morb Mortal Wkly Rep 2025;74:607–14. https://doi.org/10.15585/mmwr.mm7440a1 PMID:41379943
  8. Wiegand RE, Chickery S, Yang D-H, et al. Interim estimated effectiveness of 2025–2026 COVID-19 vaccines in adults using a test-negative design. JAMA Netw Open 2026;9:e2625152. https://doi.org/10.1001/jamanetworkopen.2026.25152 PMID:42334917
  9. Roper LE, Godfrey M, Link-Gelles R, et al. Use of additional doses of 2024–2025 COVID-19 vaccine for adults aged ≥65 years and persons aged ≥6 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:1118–23. https://doi.org/10.15585/mmwr.mm7349a2
  10. Raykin J, Rochin I, Wiegand R, et al. COVID-19 antiviral prescription receipt among outpatients aged ≥65 years—United States, June 1, 2023–September 30, 2025. MMWR Morb Mortal Wkly Rep 2026;75:69–76. https://doi.org/10.15585/mmwr.mm7506a1 PMID:41712466
Return to your place in the textFIGURE 1. Weekly percentage of laboratory test results positive for selected respiratory viruses, by virus type, month, and year — National Respiratory and Enteric Virus Surveillance System, United States, June 29, 2025–June 27, 2026*
The figure is a line graph showing the weekly percentage of laboratory test results positive for selected respiratory viruses, by virus type, month, and year in the United States during June 29, 2025–June 27, 2026, using data from the National Respiratory and Enteric Virus Surveillance System.

Abbreviations: HCoV = human coronavirus; hMPV = human metapneumovirus; PIV = parainfluenza virus; RSV = respiratory syncytial virus; RV/EV = rhinovirus/enterovirus.

* As of July 22, 2026.

Return to your place in the textFIGURE 2. Weekly percentage of laboratory test results positive for respiratory syncytial virus, by month and year — National Respiratory and Enteric Virus Surveillance System, United States, July 9, 2016–June 27, 2026*,†,§
The figure is a line graph showing the weekly percentage of laboratory test results positive for respiratory syncytial virus, by month and year in the United States during July 9, 2016–June 27, 2026, using data from the National Respiratory and Enteric Virus Surveillance System.

* Data as of July 22, 2026.

† Range of weekly percentage of positive test results reported during July 9, 2016–June 27, 2020.

§ For the 2025–2026 surveillance year, surveillance week 53 is not displayed to facilitate comparison across years.

Return to your place in the textFIGURE 3. Hospitalization rates* associated with respiratory syncytial virus†,§ (A) and COVID-19 (B), by patient age group — Respiratory Syncytial Virus Hospitalization Surveillance Network, COVID-19 Hospitalization Surveillance Network, and New Vaccine Surveillance Network, United States, July 2025–June 2026**
The figure comprises two bar graphs showing hospitalization rates associated with respiratory syncytial virus and COVID-19, by age group in the United States during July 2025–June 2026, using data from the Respiratory Syncytial Virus Hospitalization Surveillance Network, COVID-19 Hospitalization Surveillance Network, and New Vaccine Surveillance Network.

Abbreviations: COVID-NET = COVID-19 Hospitalization Surveillance Network; NVSN = New Vaccine Surveillance Network; RSV = respiratory syncytial virus; RSV-NET = Respiratory Syncytial Virus Hospitalization Surveillance Network.

* Number of hospitalizations per 100,000 persons, with 95% CIs indicated by error bars.

† RSV-NET rates are adjusted with multipliers to account for underdetection due to diagnostic test sensitivity and testing practices. Adjusted rates are presented with 95% CIs to account for multiplier uncertainty.

§ NVSN surveillance includes pediatric hospitalizations only. Population-based numerators are adjusted using multipliers for the observed number of enrolled hospitalizations to account for weeks with <7 days of surveillance, the percentage of eligible children not enrolled, sensitivity of RSV reverse transcription–polymerase chain reaction testing (87.6%) for RSV rates only, and the market share of each enrollment hospital site for the estimated proportion of acute respiratory illness hospitalizations ascertained in the catchment area. Adjusted rates were estimated per 100,000 children. 95% CIs were determined by percentiles based on 1,000 bootstrap samples for each rate to account for multiplier uncertainty. In NVSN during July 2025–2026, COVID-19 rates were 0 among children aged 2–4 years.

COVID-NET conducts population-based surveillance in which every hospitalization meeting the case definition is ascertained. Because hospitalization rates reflect actual measured rates in the catchment area population, 95% CIs are not calculated.

** As of July 22, 2026. NVSN data include July 1, 2025–June 30, 2026. COVID-NET and RSV-NET data include June 29, 2025–June 27, 2026.


Suggested citation for this article: Winn AK, Anglin O, Anderson EL, et al. Respiratory Virus Activity — United States, July 2025–June 2026. MMWR Morb Mortal Wkly Rep 2026;75:662–668. DOI: http://dx.doi.org/10.15585/mmwr.mm7545a2.

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.